Alector, Inc.

ALEC Healthcare Biotechnology

Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.

1.84 0.07 −3.66%
Market cap
$213.3M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
1/9
Altman Z
−5.15
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
300.39 266.45 215.08 180.09
Total non-current assets
34.90 26.79 24.83 22.77
Total Assets
335.29 293.24 239.92 202.86
Total current liabilities
79.96 69.50 40.97 34.24
Total non-current liabilities
197.61 193.09 188.57 178.59
Total liabilities
277.57 262.59 229.53 212.83
Common Equity (Total)
57.71 30.65 10.38 (9.97)
Shareholders Equity (Total)
57.71 30.65 10.38 (9.97)
Total Debt
9.61 9.69 9.77 9.85

Show all line items

In millions of $ except per-share values · columns are period end dates